PharmacoEconomics & Outcomes News 784, p33 - 12 Aug 2017 NICE approves nivolumab for Hodgkin’s lymphoma NICE has approved nivolumab [Opdivo, Bristol-Myers Squibb] for treating Hodgkin’s lymphoma in patients whose cancer is progressing despite undergoing autologous stem cell transplant and treatment with brentuximab vedotin. Bristol-Myers Squibb estimates that around 30 patients a year with Hodgkin lymphoma could benefit from nivolumab in the first year, with the drug keeping them well enough to have a stem cell transplant from another person’s healthy cells and potentially curing the disease. Commenting on the decision, Director of the Centre for Health Technology Evaluation at NICE Professor Carole Longson, said "these patients with Hodgkin lymphoma often have a poor prognosis with limited options left. Nivolumab offers them a promising treatment and our committee were able to recommend the drug as a cost effective use of NHS resources". NICE. NICE approval for nivolumab provides new treatment for advanced blood cancer. Internet Document : 26 Jul 2017. Available from: URL: https:// www.nice.org.uk/news/article/nice-approval-for-nivolumab-provides-new- treatment-for-advanced-blood-cancer 803261759 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784
PharmacoEconomics & Outcomes News – Springer Journals
Published: Aug 12, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera